Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          Enter the terms you wish to search for.
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              About
                              News
                              Biden-Harris Administration Moves Forward with Medicare Drug Price Negotiations to Lower Prescription Drug Costs for People with Medicare
 Navigate to:
  News
    
                                    
                                            
            
      
      
      
      Blog
    
                                    
                                            
            
      
      
      
      HHS Live
    
                                    
                                            
            
      
      
      
      Podcasts
    
                                    
                                            
            
      
      
      
      Media Guidelines for HHS EmployeesText resize icon

                    




**FOR IMMEDIATE RELEASE October 3, 2023**

        **Contact: 
                                    HHS Press Office**
          202-690-6343media@hhs.gov

          Biden-Harris Administration Moves Forward with Medicare Drug Price Negotiations to Lower Prescription Drug Costs for People with Medicare
    
    

      *10 companies manufacturing some of the costliest prescription drugs to participate in first-ever direct negotiations with Medicare*

Today, the Biden-Harris Administration announced that all 10 drug companies whose drugs were selected for price negotiation with Medicare for the first cycle of the program have decided to participate in those negotiations.  These companies manufacture some of the costliest and most commonly used prescription drugs.

These selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20%, of total Part D gross covered prescription drug costs between June 1, 2022 and May 31, 2023, which is the time period used to determine which drugs were eligible for negotiation. Medicare enrollees taking the 10 drugs covered under Part D selected for negotiation paid a total of $3.4 billion in out-of-pocket costs in 2022 for these drugs.

The 10 companies participating in the Medicare Drug Price Negotiation Program:

Drug Name
			Participating ManufacturerEliquis
			Bristol Myers SquibbJardiance
			Boehringer IngelheimXarelto
			Janssen PharmsJanuvia
			Merck Sharp DohmeFarxiga
			AstraZeneca ABEntresto
			Novartis Pharms CorpEnbrel
			Immunex CorporationImbruvica
			Pharmacyclics LLCStelara
			Janssen Biotech, Inc.Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill
			Novo Nordisk Inc.The landmark Inflation Reduction Act gave Medicare the authority to negotiate prescription drug prices for the first time in history, and, in late August, the U.S. Department of Health and Human Services (HHS) announced the 10 drugs covered under Medicare Part D selected for the first cycle of negotiation. Drug companies that manufacture these drugs have indicated that they will participate in negotiations with Medicare during the remainder of 2023 and in 2024, and any agreed-upon negotiated prices will become effective beginning in 2026.

“We are pleased that all 10 drug companies will participate in Medicare drug price negotiations. We look forward to continuing this critical work to lower health care costs for the American people and ensure seniors don’t have to choose between paying for prescription drugs or putting food on the table,” said HHS Secretary Xavier Becerra. “The Biden-Harris Administration wants Americans with Medicare to have access to innovative, life-saving treatments. Negotiating provides us a critical tool to ensure they get those prescription drugs at lower prices – just as the U.S. Department of Veterans Affairs has done for years.”

The Biden-Harris Administration has made lowering prescription drug costs and improving access to innovative therapies a key priority. Alongside other provisions in the new law that increase the affordability of health care and prescription drugs, allowing Medicare to negotiate prescription drug prices will strengthen the program’s ability to serve people with Medicare now and for generations to come. The negotiation process will consider the selected drug’s clinical benefit, the extent to which it fulfills an unmet medical need, and its impact on people who rely on Medicare, among other considerations, such as costs associated with research and development as well as costs associated with production and distribution. As a result of negotiations, people with Medicare will have access to innovative, life-saving treatments at lower costs to Medicare and taxpayers.

CMS will publish any agreed-upon negotiated prices for the selected drugs by September 1, 2024; those prices will become effective starting January 1, 2026. In future years, CMS will select for negotiation up to 15 more drugs covered under Part D for 2027, up to 15 more drugs for 2028 (including drugs covered under Part B and Part D), and up to 20 more drugs for each year after that, as required by the Inflation Reduction Act.

View a fact sheet from the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at: https://aspe.hhs.gov/reports/aspe-ira-drug-negotiation-fact-sheet.

View a CMS fact sheet on the drugs selected for the Medicare Drug Price Negotiation Program at: https://www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf.

More information on the Medicare Drug Price Negotiation Program is available at https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation.
  

    ###
    Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.Last revised: October 3, 2023

  
  
  







  Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up







  Subscribe to RSS
    

      Receive latest updates







  Related News Releases
    

      Biden-Harris Administration Finalizes Policies to Increase Access to Health Coverage for DACA Recipients
  

HHS Issues New Rule to Strengthen Nondiscrimination Protections and Advance Civil Rights in Health Care
  

New HHS Report Shows National Uninsured Rate Reached All-Time Low in 2023 After Record-Breaking ACA Enrollment Period

                    
  


Media Inquiries

For general media inquiries, please contact media@hhs.gov.







  Content created by Assistant Secretary for Public Affairs (ASPA) Content last reviewed October 3, 2023 Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​